LitCovid-sample-sentences  

PMC:7205724 / 26943-30161 JSONTXT 22 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T220 0-13 Sentence denotes 9 Conclusion
T221 14-107 Sentence denotes The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans.
T222 108-288 Sentence denotes The infection of human cells by SARS-CoV2 includes two sequential steps: attachment of the virus to the surface receptor of target cells and the fusion of viral and host membranes.
T223 289-467 Sentence denotes The former requires at least a receptor-binding domain on the SARS-CoV2 Spike protein that can interact with a cell surface receptor, for example, ACE2, expressed on human cells.
T224 468-669 Sentence denotes The latter requires at least the host protease(s) to mediate proteolytic cleavage of the SARS-CoV2 Spike protein into S1 and S2 subunits and consequently promote the fusion of viral and host membranes.
T225 670-916 Sentence denotes Also, SARS-CoV2 possesses a polybasic cleavage site that can explain the high pathogenicity of SARS-CoV2, N-glycans and O-glycans that make the dense decoration of SARS-CoV2 S protein, and cyclic regions that can interact with cell-surface GRP78.
T226 917-1099 Sentence denotes Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.
T227 1100-1296 Sentence denotes Lack of specific treatments for COVID-19 and the very time-consuming process of vaccine development lead us to trust traditional notions of immunization using passive transfer of humoral immunity.
T228 1297-1368 Sentence denotes Passive immunization can be done using plasma therapy and IVIG therapy.
T229 1369-1518 Sentence denotes Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19.
T230 1519-1626 Sentence denotes Also, SARS-CoV and SARS-CoV2 are ideally similar in the structure and the cell entry receptor and protease.
T231 1627-1776 Sentence denotes Studies show that serum from convalescent SARS patients and serum from rabbits immunized with SARS are both able to neutralize SARS-CoV2 efficiently.
T232 1777-1881 Sentence denotes However, serum from bats immunized with SARS-lice coronavirus SL-CoV Rp3 could not exert such an effect.
T233 1882-2011 Sentence denotes It is due to a noticeable degree of difference in the S1 domain in the S1 domain between the bat SL-CoV Rp3 strain and SARS-CoV2.
T234 2012-2125 Sentence denotes A short-term moderate dose of IVIG combined with moderate-dose of corticosteroids might improve patient outcomes.
T235 2126-2357 Sentence denotes Studies show that the viral RNA of SARS-CoV2 reaches its peak during the first week and then gradually decreases and that IgG and IgM begin to rise from the 10th day so that most patients have anti-viral antibodies by the 14th day.
T236 2358-2489 Sentence denotes Passive immunization protects against disease, and so it should be administered as early as possible when the patient is diagnosed.
T237 2490-2550 Sentence denotes Evidence links COVID-19 to variable degrees of inflammation.
T238 2551-2607 Sentence denotes Corticosteroids offer a potent anti-inflammatory option.
T239 2608-2720 Sentence denotes However, they do not dictate precise actions and might cause suppression of anti-viral immune responses as well.
T240 2721-2806 Sentence denotes Studies show that the use of corticosteroids might accelerate recovery from COVID-19.
T241 2807-2926 Sentence denotes There are no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death.
T242 2927-3106 Sentence denotes Moreover, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19.
T243 3107-3218 Sentence denotes Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels.